BioCentury
ARTICLE | Company News

Novartis seeks approval of QVA149 in Europe

October 26, 2012 12:59 AM UTC

Novartis AG (NYSE:NVS; SIX:NOVN) submitted a regulatory application to EMA for QVA149 to treat chronic obstructive pulmonary disease (COPD). QVA149 is a fixed-dose combination of NVA237, an inhaled long-acting muscarinic receptor antagonist (LAMA), and indacaterol, a long-acting adrenergic receptor beta 2 agonist (LABA). The submission triggers a $5 million milestone payment each to Sosei Group Corp. (Tokyo:4565) and Vectura Group plc (LSE:VEC). Novartis has worldwide rights to develop and commercialize NVA237 from the companies under a 2005 deal. ...